Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous Dosing of GW597599 Administered With Ondansetron HCL in a Female Subjects Undergoing Surgical Procedures of High Emetogenic Risk
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
St Leonards, New South Wales, Australia, 2065
- GSK Investigational Site
-
Westmead, New South Wales, Australia, 2145
- GSK Investigational Site
-
-
Victoria
-
Carlton, Victoria, Australia, 3186
- GSK Investigational Site
-
Melbourne, Victoria, Australia, 3004
- GSK Investigational Site
-
Ringwood East, Victoria, Australia, 3128
- GSK Investigational Site
-
-
Western Australia
-
Subiaco, Western Australia, Australia, 6008
- GSK Investigational Site
-
-
-
-
-
Bruxelles, Belgium, 1200
- GSK Investigational Site
-
Bruxelles, Belgium, 1070
- GSK Investigational Site
-
Gent, Belgium, 9000
- GSK Investigational Site
-
Leuven, Belgium, 3000
- GSK Investigational Site
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8Z 6R5
- GSK Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- GSK Investigational Site
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- GSK Investigational Site
-
Oshawa, Ontario, Canada, L1G 2B9
- GSK Investigational Site
-
Sudbury, Ontario, Canada, P3E 5V9
- GSK Investigational Site
-
-
Prince Edward Island
-
Charlottetown, Prince Edward Island, Canada, C1A 8T5
- GSK Investigational Site
-
-
Quebec
-
Chandler, Quebec, Canada, G0C 1K0
- GSK Investigational Site
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0W5
- GSK Investigational Site
-
-
-
-
Región Metro De Santiago
-
Santiago, Región Metro De Santiago, Chile, 8380456
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile, 7571831
- GSK Investigational Site
-
-
-
-
-
Brno, Czech Republic, 625 00
- GSK Investigational Site
-
Jihlava, Czech Republic, 586 33
- GSK Investigational Site
-
Olomouc, Czech Republic, 775 20
- GSK Investigational Site
-
Ostrava - Poruba, Czech Republic, 708 52
- GSK Investigational Site
-
-
-
-
-
Helsinki, Finland, 00029
- GSK Investigational Site
-
Kuopio, Finland, 70210
- GSK Investigational Site
-
-
-
-
-
Roosendaal, Netherlands, 4708 AE
- GSK Investigational Site
-
Rotterdam, Netherlands, 3083 AN
- GSK Investigational Site
-
Rotterdam, Netherlands, 3011 TD
- GSK Investigational Site
-
-
-
-
-
Poznan, Poland, 60-535
- GSK Investigational Site
-
Warszawa, Poland, 02-781
- GSK Investigational Site
-
Warszawa, Poland, 02-507
- GSK Investigational Site
-
-
-
-
-
Arcadia, Pretoria, South Africa, 0083
- GSK Investigational Site
-
Bloemfontein, South Africa, 9301
- GSK Investigational Site
-
-
-
-
-
Istanbul, Turkey, 34303
- GSK Investigational Site
-
Istanbul, Turkey
- GSK Investigational Site
-
-
-
-
Essex
-
Chelmsford, Essex, United Kingdom, CM1 7ET
- GSK Investigational Site
-
-
Northamptonshire
-
Northampton, Northamptonshire, United Kingdom, NN1 5BD
- GSK Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- GSK Investigational Site
-
-
California
-
Glendale, California, United States, 91206
- GSK Investigational Site
-
Laguna Hills, California, United States, 95660
- GSK Investigational Site
-
Los Angeles, California, United States, 90048
- GSK Investigational Site
-
Los Angeles, California, United States, 90089
- GSK Investigational Site
-
Pasadena, California, United States, 91109
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, United States, 33067
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- GSK Investigational Site
-
-
New York
-
Albany, New York, United States, 12208
- GSK Investigational Site
-
New York, New York, United States, 10021
- GSK Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- GSK Investigational Site
-
Raleigh, North Carolina, United States, 27609
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75390-9135
- GSK Investigational Site
-
Houston, Texas, United States, 77024
- GSK Investigational Site
-
-
Washington
-
Spokane, Washington, United States, 99204
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- known risk factors for PONV.
- Undergoing gynecological or gallbladder surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The number of subjects who achieve a complete antiemetic response during the first 24 hour evaluation period following the emergence from anesthesia.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
The number of subjects who achieve a complete antiemetic response during each subsequent 24 hour evaluation period (up to 120 hours) following the emergence from anesthesia.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NKO101287
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.